TQB3473 for persistent or chronic ITP in adults
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an experimental oral medication called TQB3473 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets causing low counts and bleeding risk. The goal is to see if the drug can safely improve platelet counts and reduce bleeding symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You should be generally active and able to care for yourself (ECOG 0-1)
- Your bleeding symptoms should be minimal (WHO bleeding score 0-1) and stable
- If you have already been in the earlier TQB3473 study, you must meet one of the study's conditions to continue
- For new participants, your diagnosis of primary ITP must be more than 3 months old and you must have failed at least one prior standard treatment
- Your platelet count must be below 30,000 (with no single count above 35,000) in recent tests
- You can be on no more than one other ITP treatment, and it must be at a stable dose for at least 4 weeks (2 weeks for steroids)
- You must be willing to use effective birth control during the study and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
This trial tests a new medicine for children with a condition called immune thrombocytopenia (ITP), which causes low blood platelets and easy bruising or bleeding. It may help increase platelet counts when standard treatments haven't worked.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.